Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Prescriptions for insulin glargine-yfgn (Semglee) rapidly increased when its status switched from a standard biosimilar to ...

Purpose: The pharmacology, pharmacokinetics, efficacy and tolerability, safety, drug interactions, dosage and administration, cost, and place in therapy of insulin detemir are reviewed. Summary ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

Semglee is a long-acting human insulin analog indicated to improve ... Do not use during episodes of hypoglycemia or if hypersensitive to insulin glargine or it’s excipients.

Inclusion of basal insulin glargine in multiple daily injection (MDI) regimens decreases glycemic variability in adolescents with type 1 diabetes mellitus (T1DM), according to US researchers.

Both Toujeo and Lantus are once-daily formulations of insulin glargine ... from the EMA’s Committee for Medicinal Products for Human Use (CHMP) which if endorsed would extend the use of Toujeo ...

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has approved the insulin glargine cartridge developed by China’s Gan & Lee Pharmaceuticals, marking the first biosimilar of its kind ...